메뉴 건너뛰기




Volumn 28, Issue 3, 2014, Pages 491-505

Targeted Therapies for Cutaneous Melanoma

Author keywords

BRAF; MAPK signaling; MEK; Melanoma; NRAS; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BINIMETINIB; COBIMETINIB; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF INHIBITOR; SORAFENIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

EID: 84901607500     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.02.003     Document Type: Review
Times cited : (11)

References (88)
  • 1
    • 77956156031 scopus 로고    scopus 로고
    • Ultraviolet radiation and skin cancer
    • Narayanan D.L., Saladi R.N., Fox J.L. Ultraviolet radiation and skin cancer. Int J Dermatol 2010, 49(9):978-986.
    • (2010) Int J Dermatol , vol.49 , Issue.9 , pp. 978-986
    • Narayanan, D.L.1    Saladi, R.N.2    Fox, J.L.3
  • 2
    • 74949143594 scopus 로고    scopus 로고
    • Final version of 2009 AJCC melanoma staging and classification
    • Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27(36):6199-6206.
    • (2009) JClin Oncol , vol.27 , Issue.36 , pp. 6199-6206
    • Balch, C.M.1    Gershenwald, J.E.2    Soong, S.J.3
  • 3
    • 33847212780 scopus 로고    scopus 로고
    • Drug resistance in melanoma: new perspectives
    • La Porta C.A. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007, 14(4):387-391.
    • (2007) Curr Med Chem , vol.14 , Issue.4 , pp. 387-391
    • La Porta, C.A.1
  • 4
    • 70350359819 scopus 로고    scopus 로고
    • Chemotherapy and biologic therapies for melanoma: do they work?
    • Jilaveanu L.B., Aziz S.A., Kluger H.M. Chemotherapy and biologic therapies for melanoma: do they work?. Clin Dermatol 2009, 27(6):614-625.
    • (2009) Clin Dermatol , vol.27 , Issue.6 , pp. 614-625
    • Jilaveanu, L.B.1    Aziz, S.A.2    Kluger, H.M.3
  • 5
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364(26):2507-2516.
    • (2011) NEngl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 6
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEngl J Med 2011, 364(26):2517-2526.
    • (2011) NEngl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 7
    • 84901627193 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [Abstract 24]. Presented at: European Cancer Congress. Amsterdam, The Netherlands, September 27-October 1, 2013.
    • Schadendorf D, Hodi FS, Robert C, etal. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [Abstract 24]. Presented at: European Cancer Congress. Amsterdam, The Netherlands, September 27-October 1, 2013.
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3
  • 8
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 2012, 366(26):2455-2465.
    • (2012) NEngl J Med , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 9
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366(26):2443-2454.
    • (2012) NEngl J Med , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 10
    • 30944447568 scopus 로고    scopus 로고
    • The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions
    • Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24(1):21-44.
    • (2006) Growth Factors , vol.24 , Issue.1 , pp. 21-44
    • Yoon, S.1    Seger, R.2
  • 11
    • 84874518093 scopus 로고    scopus 로고
    • Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma
    • Greaves W.O., Verma S., Patel K.P., et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. JMol Diagn 2013, 15(2):220-226.
    • (2013) JMol Diagn , vol.15 , Issue.2 , pp. 220-226
    • Greaves, W.O.1    Verma, S.2    Patel, K.P.3
  • 12
    • 84978034236 scopus 로고    scopus 로고
    • Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    • Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. JClin Oncol 2011, 29(10):1239-1246.
    • (2011) JClin Oncol , vol.29 , Issue.10 , pp. 1239-1246
    • Long, G.V.1    Menzies, A.M.2    Nagrial, A.M.3
  • 13
    • 40849094167 scopus 로고    scopus 로고
    • Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
    • Platz A., Egyhazi S., Ringborg U., et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008, 1(4):395-405.
    • (2008) Mol Oncol , vol.1 , Issue.4 , pp. 395-405
    • Platz, A.1    Egyhazi, S.2    Ringborg, U.3
  • 14
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
    • (2002) Nature , vol.417 , Issue.6892 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 15
    • 33749021085 scopus 로고    scopus 로고
    • Somatic activation of KIT in distinct subtypes of melanoma
    • Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. JClin Oncol 2006, 24(26):4340-4346.
    • (2006) JClin Oncol , vol.24 , Issue.26 , pp. 4340-4346
    • Curtin, J.A.1    Busam, K.2    Pinkel, D.3
  • 16
    • 58149260596 scopus 로고    scopus 로고
    • KIT gene mutations and copy number in melanoma subtypes
    • Beadling C., Jacobson-Dunlop E., Hodi F.S., et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14(21):6821-6828.
    • (2008) Clin Cancer Res , vol.14 , Issue.21 , pp. 6821-6828
    • Beadling, C.1    Jacobson-Dunlop, E.2    Hodi, F.S.3
  • 17
    • 79960708519 scopus 로고    scopus 로고
    • Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification
    • Guo J., Si L., Kong Y., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. JClin Oncol 2011, 29(21):2904-2909.
    • (2011) JClin Oncol , vol.29 , Issue.21 , pp. 2904-2909
    • Guo, J.1    Si, L.2    Kong, Y.3
  • 18
    • 80052358465 scopus 로고    scopus 로고
    • Treatment implications of the emerging molecular classification system for melanoma
    • Romano E., Schwartz G.K., Chapman P.B., et al. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011, 12(9):913-922.
    • (2011) Lancet Oncol , vol.12 , Issue.9 , pp. 913-922
    • Romano, E.1    Schwartz, G.K.2    Chapman, P.B.3
  • 19
    • 0037228055 scopus 로고    scopus 로고
    • High frequency of BRAF mutations in nevi
    • Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
    • (2003) Nat Genet , vol.33 , Issue.1 , pp. 19-20
    • Pollock, P.M.1    Harper, U.L.2    Hansen, K.S.3
  • 20
    • 77953500573 scopus 로고    scopus 로고
    • Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study
    • Gast A., Scherer D., Chen B., et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010, 49(8):733-745.
    • (2010) Genes Chromosomes Cancer , vol.49 , Issue.8 , pp. 733-745
    • Gast, A.1    Scherer, D.2    Chen, B.3
  • 21
    • 1442274619 scopus 로고    scopus 로고
    • Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
    • Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. JInvest Dermatol 2004, 122(2):337-341.
    • (2004) JInvest Dermatol , vol.122 , Issue.2 , pp. 337-341
    • Tsao, H.1    Goel, V.2    Wu, H.3
  • 22
    • 55749088393 scopus 로고    scopus 로고
    • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    • Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10):3129-3140.
    • (2008) Mol Cancer Ther , vol.7 , Issue.10 , pp. 3129-3140
    • Wilhelm, S.M.1    Adnane, L.2    Newell, P.3
  • 23
    • 33748325763 scopus 로고    scopus 로고
    • Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis
    • Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95(5):581-586.
    • (2006) Br J Cancer , vol.95 , Issue.5 , pp. 581-586
    • Eisen, T.1    Ahmad, T.2    Flaherty, K.T.3
  • 24
    • 78650824497 scopus 로고    scopus 로고
    • Aphase II trial of sorafenib in metastatic melanoma with tissue correlates
    • Ott P.A., Hamilton A., Min C., et al. Aphase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010, 5(12):e15588.
    • (2010) PLoS One , vol.5 , Issue.12
    • Ott, P.A.1    Hamilton, A.2    Min, C.3
  • 25
    • 84873346707 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
    • Flaherty K.T., Lee S.J., Zhao F., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. JClin Oncol 2013, 31(3):373-379.
    • (2013) JClin Oncol , vol.31 , Issue.3 , pp. 373-379
    • Flaherty, K.T.1    Lee, S.J.2    Zhao, F.3
  • 26
    • 51049095131 scopus 로고    scopus 로고
    • Aphase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
    • Flaherty K.T., Schiller J., Schuchter L.M., et al. Aphase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008, 14(15):4836-4842.
    • (2008) Clin Cancer Res , vol.14 , Issue.15 , pp. 4836-4842
    • Flaherty, K.T.1    Schiller, J.2    Schuchter, L.M.3
  • 27
    • 33846212284 scopus 로고    scopus 로고
    • Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    • Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66(24):11851-11858.
    • (2006) Cancer Res , vol.66 , Issue.24 , pp. 11851-11858
    • Liu, L.1    Cao, Y.2    Chen, C.3
  • 28
    • 42949149240 scopus 로고    scopus 로고
    • Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    • Tsai J., Lee J.T., Wang W., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105(8):3041-3046.
    • (2008) Proc Natl Acad Sci USA , vol.105 , Issue.8 , pp. 3041-3046
    • Tsai, J.1    Lee, J.T.2    Wang, W.3
  • 29
    • 77957089182 scopus 로고    scopus 로고
    • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    • Joseph E.W., Pratilas C.A., Poulikakos P.I., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010, 107(33):14903-14908.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.33 , pp. 14903-14908
    • Joseph, E.W.1    Pratilas, C.A.2    Poulikakos, P.I.3
  • 30
    • 77954376912 scopus 로고    scopus 로고
    • RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    • Yang H., Higgins B., Kolinsky K., et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13):5518-5527.
    • (2010) Cancer Res , vol.70 , Issue.13 , pp. 5518-5527
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3
  • 31
    • 77949685981 scopus 로고    scopus 로고
    • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • Hatzivassiliou G., Song K., Yen I., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464(7287):431-435.
    • (2010) Nature , vol.464 , Issue.7287 , pp. 431-435
    • Hatzivassiliou, G.1    Song, K.2    Yen, I.3
  • 32
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos P.I., Zhang C., Bollag G., et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287):427-430.
    • (2010) Nature , vol.464 , Issue.7287 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3
  • 33
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEngl J Med 2010, 363(9):809-819.
    • (2010) NEngl J Med , vol.363 , Issue.9 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 34
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.
    • (2010) Nature , vol.467 , Issue.7315 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3
  • 35
    • 84863746052 scopus 로고    scopus 로고
    • 18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
    • 18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. JClin Oncol 2012, 30(14):1628-1634.
    • (2012) JClin Oncol , vol.30 , Issue.14 , pp. 1628-1634
    • McArthur, G.A.1    Puzanov, I.2    Amaravadi, R.3
  • 36
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. NEngl J Med 2012, 366(8):707-714.
    • (2012) NEngl J Med , vol.366 , Issue.8 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 37
    • 39149104690 scopus 로고    scopus 로고
    • Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    • Korn E.L., Liu P.Y., Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. JClin Oncol 2008, 26(4):527-534.
    • (2008) JClin Oncol , vol.26 , Issue.4 , pp. 527-534
    • Korn, E.L.1    Liu, P.Y.2    Lee, S.J.3
  • 38
    • 84896714827 scopus 로고    scopus 로고
    • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    • McArthur G.A., Chapman P.B., Robert C., et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15(3):323-332.
    • (2014) Lancet Oncol , vol.15 , Issue.3 , pp. 323-332
    • McArthur, G.A.1    Chapman, P.B.2    Robert, C.3
  • 39
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    • Falchook G.S., Long G.V., Kurzrock R., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379(9829):1893-1901.
    • (2012) Lancet , vol.379 , Issue.9829 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 40
    • 84891648456 scopus 로고    scopus 로고
    • Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
    • Ascierto P.A., Minor D., Ribas A., et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. JClin Oncol 2013, 31(26):3205-3211.
    • (2013) JClin Oncol , vol.31 , Issue.26 , pp. 3205-3211
    • Ascierto, P.A.1    Minor, D.2    Ribas, A.3
  • 41
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365.
    • (2012) Lancet , vol.380 , Issue.9839 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 42
    • 84867555830 scopus 로고    scopus 로고
    • Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma
    • Anderson S., Bloom K.J., Vallera D.U., et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11):1385-1391.
    • (2012) Arch Pathol Lab Med , vol.136 , Issue.11 , pp. 1385-1391
    • Anderson, S.1    Bloom, K.J.2    Vallera, D.U.3
  • 43
    • 79953781233 scopus 로고    scopus 로고
    • Prognostic factors for survival in melanoma patients with brain metastases
    • Davies M.A., Liu P., McIntyre S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117(8):1687-1696.
    • (2011) Cancer , vol.117 , Issue.8 , pp. 1687-1696
    • Davies, M.A.1    Liu, P.2    McIntyre, S.3
  • 44
    • 2142644507 scopus 로고    scopus 로고
    • Determinants of outcome in melanoma patients with cerebral metastases
    • Fife K.M., Colman M.H., Stevens G.N., et al. Determinants of outcome in melanoma patients with cerebral metastases. JClin Oncol 2004, 22(7):1293-1300.
    • (2004) JClin Oncol , vol.22 , Issue.7 , pp. 1293-1300
    • Fife, K.M.1    Colman, M.H.2    Stevens, G.N.3
  • 45
    • 2942689983 scopus 로고    scopus 로고
    • Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study
    • Agarwala S.S., Kirkwood J.M., Gore M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. JClin Oncol 2004, 22(11):2101-2107.
    • (2004) JClin Oncol , vol.22 , Issue.11 , pp. 2101-2107
    • Agarwala, S.S.1    Kirkwood, J.M.2    Gore, M.3
  • 46
    • 84860446616 scopus 로고    scopus 로고
    • Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
    • Margolin K., Ernstoff M.S., Hamid O., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13(5):459-465.
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 459-465
    • Margolin, K.1    Ernstoff, M.S.2    Hamid, O.3
  • 47
    • 0037331446 scopus 로고    scopus 로고
    • Aprospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma
    • Mornex F., Thomas L., Mohr P., et al. Aprospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003, 13(1):97-103.
    • (2003) Melanoma Res , vol.13 , Issue.1 , pp. 97-103
    • Mornex, F.1    Thomas, L.2    Mohr, P.3
  • 48
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    • Long G.V., Trefzer U., Davies M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(11):1087-1095.
    • (2012) Lancet Oncol , vol.13 , Issue.11 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3
  • 49
    • 79851509964 scopus 로고    scopus 로고
    • The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors
    • Buckmelter A.J., Ren L., Laird E.R., et al. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. Bioorg Med Chem Lett 2011, 21(4):1248-1252.
    • (2011) Bioorg Med Chem Lett , vol.21 , Issue.4 , pp. 1248-1252
    • Buckmelter, A.J.1    Ren, L.2    Laird, E.R.3
  • 50
    • 84893661769 scopus 로고    scopus 로고
    • Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
    • Dummer R., Goldinger S.M., Turtschi C.P., et al. Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50(3):611-621.
    • (2014) Eur J Cancer , vol.50 , Issue.3 , pp. 611-621
    • Dummer, R.1    Goldinger, S.M.2    Turtschi, C.P.3
  • 51
    • 34250221510 scopus 로고    scopus 로고
    • Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm
    • Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. JClin Oncol 2007, 25(16):2306-2312.
    • (2007) JClin Oncol , vol.25 , Issue.16 , pp. 2306-2312
    • Gerstner, E.R.1    Fine, R.L.2
  • 52
    • 84862908097 scopus 로고    scopus 로고
    • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    • Su F., Viros A., Milagre C., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. NEngl J Med 2012, 366(3):207-215.
    • (2012) NEngl J Med , vol.366 , Issue.3 , pp. 207-215
    • Su, F.1    Viros, A.2    Milagre, C.3
  • 53
    • 84862908526 scopus 로고    scopus 로고
    • RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
    • Oberholzer P.A., Kee D., Dziunycz P., et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. JClin Oncol 2012, 30(3):316-321.
    • (2012) JClin Oncol , vol.30 , Issue.3 , pp. 316-321
    • Oberholzer, P.A.1    Kee, D.2    Dziunycz, P.3
  • 54
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367(18):1694-1703.
    • (2012) NEngl J Med , vol.367 , Issue.18 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 55
    • 84863463901 scopus 로고    scopus 로고
    • Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
    • Zimmer L., Hillen U., Livingstone E., et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. JClin Oncol 2012, 30(19):2375-2383.
    • (2012) JClin Oncol , vol.30 , Issue.19 , pp. 2375-2383
    • Zimmer, L.1    Hillen, U.2    Livingstone, E.3
  • 56
    • 84871037064 scopus 로고    scopus 로고
    • Progression of RAS-mutant leukemia during RAF inhibitor treatment
    • Callahan M.K., Rampal R., Harding J.J., et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. NEngl J Med 2012, 367(24):2316-2321.
    • (2012) NEngl J Med , vol.367 , Issue.24 , pp. 2316-2321
    • Callahan, M.K.1    Rampal, R.2    Harding, J.J.3
  • 57
    • 84894375817 scopus 로고    scopus 로고
    • BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition
    • Andrews M., Behren A., Chiohn F., et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. JClin Oncol 2013, 31(35):e448-e451.
    • (2013) JClin Oncol , vol.31 , Issue.35
    • Andrews, M.1    Behren, A.2    Chiohn, F.3
  • 58
    • 84879496934 scopus 로고    scopus 로고
    • Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
    • Trunzer K., Pavlick A.C., Schuchter L., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. JClin Oncol 2013, 31(14):1767-1774.
    • (2013) JClin Oncol , vol.31 , Issue.14 , pp. 1767-1774
    • Trunzer, K.1    Pavlick, A.C.2    Schuchter, L.3
  • 59
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
    • (2010) Nature , vol.468 , Issue.7326 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3
  • 60
    • 84859183431 scopus 로고    scopus 로고
    • Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    • Shi H., Moriceau G., Kong X., et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012, 3:724.
    • (2012) Nat Commun , vol.3 , pp. 724
    • Shi, H.1    Moriceau, G.2    Kong, X.3
  • 61
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos P.I., Persaud Y., Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480(7377):387-390.
    • (2011) Nature , vol.480 , Issue.7377 , pp. 387-390
    • Poulikakos, P.I.1    Persaud, Y.2    Janakiraman, M.3
  • 62
    • 78650309875 scopus 로고    scopus 로고
    • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    • Johannessen C.M., Boehm J.S., Kim S.Y., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326):968-972.
    • (2010) Nature , vol.468 , Issue.7326 , pp. 968-972
    • Johannessen, C.M.1    Boehm, J.S.2    Kim, S.Y.3
  • 63
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • Straussman R., Morikawa T., Shee K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487(7408):500-504.
    • (2012) Nature , vol.487 , Issue.7408 , pp. 500-504
    • Straussman, R.1    Morikawa, T.2    Shee, K.3
  • 64
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • Villanueva J., Vultur A., Lee J.T., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
    • (2010) Cancer Cell , vol.18 , Issue.6 , pp. 683-695
    • Villanueva, J.1    Vultur, A.2    Lee, J.T.3
  • 65
    • 84864286442 scopus 로고    scopus 로고
    • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
    • Wilson T.R., Fridlyand J., Yan Y., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487(7408):505-509.
    • (2012) Nature , vol.487 , Issue.7408 , pp. 505-509
    • Wilson, T.R.1    Fridlyand, J.2    Yan, Y.3
  • 66
    • 84864994126 scopus 로고    scopus 로고
    • Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma
    • Yadav V., Zhang X., Liu J., et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. JBiol Chem 2012, 287(33):28087-28098.
    • (2012) JBiol Chem , vol.287 , Issue.33 , pp. 28087-28098
    • Yadav, V.1    Zhang, X.2    Liu, J.3
  • 67
    • 31144453233 scopus 로고    scopus 로고
    • BRAF mutation predicts sensitivity to MEK inhibition
    • Solit D.B., Garraway L.A., Pratilas C.A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439(7074):358-362.
    • (2006) Nature , vol.439 , Issue.7074 , pp. 358-362
    • Solit, D.B.1    Garraway, L.A.2    Pratilas, C.A.3
  • 68
    • 14844285975 scopus 로고    scopus 로고
    • Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    • Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. JClin Oncol 2004, 22(22):4456-4462.
    • (2004) JClin Oncol , vol.22 , Issue.22 , pp. 4456-4462
    • Rinehart, J.1    Adjei, A.A.2    Lorusso, P.M.3
  • 69
    • 77949766280 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
    • LoRusso P.M., Krishnamurthi S.S., Rinehart J.J., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010, 16(6):1924-1937.
    • (2010) Clin Cancer Res , vol.16 , Issue.6 , pp. 1924-1937
    • LoRusso, P.M.1    Krishnamurthi, S.S.2    Rinehart, J.J.3
  • 70
    • 84856009717 scopus 로고    scopus 로고
    • Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
    • Kirkwood J.M., Bastholt L., Robert C., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18(2):555-567.
    • (2012) Clin Cancer Res , vol.18 , Issue.2 , pp. 555-567
    • Kirkwood, J.M.1    Bastholt, L.2    Robert, C.3
  • 71
    • 79952261716 scopus 로고    scopus 로고
    • GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained invivo pathway inhibition
    • Gilmartin A.G., Bleam M.R., Groy A., et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained invivo pathway inhibition. Clin Cancer Res 2011, 17(5):989-1000.
    • (2011) Clin Cancer Res , vol.17 , Issue.5 , pp. 989-1000
    • Gilmartin, A.G.1    Bleam, M.R.2    Groy, A.3
  • 72
    • 84901611389 scopus 로고    scopus 로고
    • Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study [Abstract 3703]. Paper presented at: European Cancer Congress. Amsterdam, The Netherlands. September 27-October 1, 2013. Available at: .
    • McArthur G, Gonzalez R, Pavlick A, etal. Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study [Abstract 3703]. Paper presented at: European Cancer Congress. Amsterdam, The Netherlands. September 27-October 1, 2013. Available at:. http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx?abstractid=7015.
    • McArthur, G.1    Gonzalez, R.2    Pavlick, A.3
  • 73
    • 80051873884 scopus 로고    scopus 로고
    • Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
    • Devitt B., Liu W., Salemi R., et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011, 24(4):666-672.
    • (2011) Pigment Cell Melanoma Res , vol.24 , Issue.4 , pp. 666-672
    • Devitt, B.1    Liu, W.2    Salemi, R.3
  • 74
    • 84864722943 scopus 로고    scopus 로고
    • NRAS mutation status is an independent prognostic factor in metastatic melanoma
    • Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118(16):4014-4023.
    • (2012) Cancer , vol.118 , Issue.16 , pp. 4014-4023
    • Jakob, J.A.1    Bassett, R.L.2    Ng, C.S.3
  • 75
    • 17644383337 scopus 로고    scopus 로고
    • Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
    • Eskandarpour M., Kiaii S., Zhu C., et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005, 115(1):65-73.
    • (2005) Int J Cancer , vol.115 , Issue.1 , pp. 65-73
    • Eskandarpour, M.1    Kiaii, S.2    Zhu, C.3
  • 76
    • 79960051265 scopus 로고    scopus 로고
    • Therapeutic strategies for targeting ras proteins
    • Gysin S., Salt M., Young A., et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2(3):359-372.
    • (2011) Genes Cancer , vol.2 , Issue.3 , pp. 359-372
    • Gysin, S.1    Salt, M.2    Young, A.3
  • 77
    • 84859463692 scopus 로고    scopus 로고
    • Targeting NRAS in melanoma
    • Kelleher F.C., McArthur G.A. Targeting NRAS in melanoma. Cancer J 2012, 18(2):132-136.
    • (2012) Cancer J , vol.18 , Issue.2 , pp. 132-136
    • Kelleher, F.C.1    McArthur, G.A.2
  • 78
    • 84870289371 scopus 로고    scopus 로고
    • Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
    • Kwong L.N., Costello J.C., Liu H., et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18(10):1503-1510.
    • (2012) Nat Med , vol.18 , Issue.10 , pp. 1503-1510
    • Kwong, L.N.1    Costello, J.C.2    Liu, H.3
  • 79
    • 84875235432 scopus 로고    scopus 로고
    • MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    • Ascierto P.A., Schadendorf D., Berking C., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14(3):249-256.
    • (2013) Lancet Oncol , vol.14 , Issue.3 , pp. 249-256
    • Ascierto, P.A.1    Schadendorf, D.2    Berking, C.3
  • 80
    • 84901588055 scopus 로고    scopus 로고
    • Pimasertib (MSC1936369B/AS703026), aselective oral MEK1/2 inhibitor, shows clinical activity in melanoma
    • Delord J.P., Houédé N., Awada A., et al. Pimasertib (MSC1936369B/AS703026), aselective oral MEK1/2 inhibitor, shows clinical activity in melanoma. Eur J Cancer 2012, 48(Suppl):190.
    • (2012) Eur J Cancer , vol.48 , Issue.SUPPL , pp. 190
    • Delord, J.P.1    Houédé, N.2    Awada, A.3
  • 81
    • 27844567142 scopus 로고    scopus 로고
    • Distinct sets of genetic alterations in melanoma
    • Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. NEngl J Med 2005, 353(20):2135-2147.
    • (2005) NEngl J Med , vol.353 , Issue.20 , pp. 2135-2147
    • Curtin, J.A.1    Fridlyand, J.2    Kageshita, T.3
  • 82
    • 79958066836 scopus 로고    scopus 로고
    • KIT as a therapeutic target in metastatic melanoma
    • Carvajal R.D., Antonescu C.R., Wolchok J.D., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305(22):2327-2334.
    • (2011) JAMA , vol.305 , Issue.22 , pp. 2327-2334
    • Carvajal, R.D.1    Antonescu, C.R.2    Wolchok, J.D.3
  • 83
    • 84881512367 scopus 로고    scopus 로고
    • Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
    • Hodi F.S., Corless C.L., Giobbie-Hurder A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. JClin Oncol 2013, 31(26):3182-3190.
    • (2013) JClin Oncol , vol.31 , Issue.26 , pp. 3182-3190
    • Hodi, F.S.1    Corless, C.L.2    Giobbie-Hurder, A.3
  • 84
    • 57049109807 scopus 로고    scopus 로고
    • Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
    • Quintas-Cardama A., Lazar A.J., Woodman S.E., et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008, 5(12):737-740.
    • (2008) Nat Clin Pract Oncol , vol.5 , Issue.12 , pp. 737-740
    • Quintas-Cardama, A.1    Lazar, A.J.2    Woodman, S.E.3
  • 85
    • 68849093078 scopus 로고    scopus 로고
    • Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates
    • Woodman S.E., Trent J.C., Stemke-Hale K., et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009, 8(8):2079-2085.
    • (2009) Mol Cancer Ther , vol.8 , Issue.8 , pp. 2079-2085
    • Woodman, S.E.1    Trent, J.C.2    Stemke-Hale, K.3
  • 86
    • 84857760658 scopus 로고    scopus 로고
    • Sunitinib therapy for melanoma patients with KIT mutations
    • Minor D.R., Kashani-Sabet M., Garrido M., et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 2012, 18(5):1457-1463.
    • (2012) Clin Cancer Res , vol.18 , Issue.5 , pp. 1457-1463
    • Minor, D.R.1    Kashani-Sabet, M.2    Garrido, M.3
  • 87
    • 84867867288 scopus 로고    scopus 로고
    • Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
    • Cho J.H., Kim K.M., Kwon M., et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012, 30(5):2008-2014.
    • (2012) Invest New Drugs , vol.30 , Issue.5 , pp. 2008-2014
    • Cho, J.H.1    Kim, K.M.2    Kwon, M.3
  • 88
    • 84871760899 scopus 로고    scopus 로고
    • Current and emerging strategies for the management ofimatinib-refractory advanced gastrointestinal stromal tumors
    • Kee D., Zalcberg J.R. Current and emerging strategies for the management ofimatinib-refractory advanced gastrointestinal stromal tumors. Ther Adv Med Oncol 2012, 4(5):255-270.
    • (2012) Ther Adv Med Oncol , vol.4 , Issue.5 , pp. 255-270
    • Kee, D.1    Zalcberg, J.R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.